# Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System

> **NCT01597570** · PHASE3 · TERMINATED · sponsor: **Taewoong Medical Co., Ltd.** · enrollment: 52 (actual)

## Conditions studied

- The Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter Removal

## Interventions

- **DEVICE:** Vascular Closure Device

## Key facts

- **NCT ID:** NCT01597570
- **Lead sponsor:** Taewoong Medical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2012-12-10
- **Final completion:** 2012-12-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597570, "Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01597570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*